AC Immune Past Earnings Performance
Past criteria checks 0/6
AC Immune's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 67.5% per year.
Key information
-33.9%
Earnings growth rate
-31.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -67.5% |
| Return on equity | -37.7% |
| Net Margin | -368.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Revenue & Expenses Breakdown
How AC Immune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 15 | -55 | 16 | 0 |
| 31 Dec 23 | 15 | -54 | 15 | 0 |
| 30 Sep 23 | 0 | -68 | 15 | 0 |
| 30 Jun 23 | 4 | -67 | 15 | 0 |
| 31 Mar 23 | 4 | -69 | 16 | 0 |
| 31 Dec 22 | 4 | -71 | 16 | 0 |
| 30 Sep 22 | 4 | -73 | 14 | 0 |
| 30 Jun 22 | 0 | -76 | 16 | 0 |
| 31 Mar 22 | 0 | -75 | 17 | 0 |
| 31 Dec 21 | 0 | -73 | 18 | 0 |
| 30 Sep 21 | 1 | -71 | 19 | 0 |
| 30 Jun 21 | 2 | -74 | 19 | 0 |
| 31 Mar 21 | 3 | -71 | 18 | 0 |
| 31 Dec 20 | 15 | -62 | 19 | 0 |
| 30 Sep 20 | 15 | -62 | 19 | 0 |
| 30 Jun 20 | 47 | -25 | 18 | 0 |
| 31 Mar 20 | 48 | -26 | 17 | 0 |
| 31 Dec 19 | 110 | 45 | 16 | 0 |
| 30 Sep 19 | 111 | 50 | 15 | 0 |
| 30 Jun 19 | 80 | 18 | 14 | 0 |
| 31 Mar 19 | 81 | 24 | 13 | 0 |
| 31 Dec 18 | 7 | -51 | 12 | 0 |
| 30 Sep 18 | 22 | -32 | 12 | 0 |
| 30 Jun 18 | 21 | -27 | 11 | 0 |
| 31 Mar 18 | 20 | -29 | 10 | 0 |
| 31 Dec 17 | 20 | -26 | 10 | 0 |
| 30 Sep 17 | 5 | -35 | 10 | 0 |
| 30 Jun 17 | 6 | -36 | 10 | 0 |
| 31 Mar 17 | 25 | -10 | 9 | 0 |
| 31 Dec 16 | 23 | -7 | 8 | 0 |
| 30 Sep 16 | 22 | -8 | 5 | 0 |
| 30 Jun 16 | 45 | 21 | 4 | 0 |
| 31 Mar 16 | 39 | 17 | 4 | 0 |
| 31 Dec 15 | 39 | 20 | 3 | 0 |
| 30 Sep 15 | 65 | 46 | 4 | 0 |
| 30 Jun 15 | 41 | 21 | 4 | 0 |
| 31 Mar 15 | 28 | 10 | 3 | 0 |
| 31 Dec 14 | 30 | 11 | 3 | 0 |
| 31 Dec 13 | 9 | -11 | 3 | 0 |
Quality Earnings: ACIU is currently unprofitable.
Growing Profit Margin: ACIU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACIU is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare ACIU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACIU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ACIU has a negative Return on Equity (-37.73%), as it is currently unprofitable.